Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

119
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
119
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

161
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
161
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

144
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
144
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

160
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
160
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

92
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
92
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

107
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
107

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paired and AB/BA Cross-Over Design in Early Phase Clinical Trials: A Closer Look at Within-Subject Variance Bias.

Pharmaceutical statistics·2026
Same author

Conformational dynamics of CRISPR-Cas type I-F-HNH inform nickase engineering in a cascade scaffold.

Nucleic acids research·2026
Same author

ADPO: automatic-differentiation-assisted parametric optimization.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

Pirana and Integrated PMX Tools, a Workbench for NONMEM, NLME, pyDarwin, and RsNLME.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Evaluation of Incurred Subject Period Re-analysis (ISPR) as a Tool to Distinguish Fraudulent Pharmacokinetic Profile Pairs from Non-fraudulent Pairs.

The AAPS journal·2024
Same author

Rejoinder to the 'Letter to the Editor' on "Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies".

The AAPS journal·2024

Related Experiment Video

Updated: Dec 29, 2025

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
11:58

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan

Published on: June 29, 2018

9.9K

Reference Datasets for Studies in a Replicate Design Intended for Average Bioequivalence with Expanding Limits.

Helmut Schütz1, Detlew Labes2, Michael Tomashevskiy3

  • 1BEBAC, Neubaugasse 36/11, 1070, Vienna, Austria. helmut.schuetz@bebac.at.

The AAPS Journal
|February 9, 2020
PubMed
Summary

This study provides 30 reference datasets for validating bioequivalence software in replicate designs. All tested software packages accurately estimated key metrics like CVwR and Method A, ensuring reliable bioequivalence trial evaluations.

Keywords:
average bioequivalence with expanding limitsblack box software validationreference scalingreplicate designs

More Related Videos

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.5K
Rup (RNA-seq Usability Assessment Pipeline) - Quality Control for Bulk RNA-seq Experiments in Eukaryotes
05:07

Rup (RNA-seq Usability Assessment Pipeline) - Quality Control for Bulk RNA-seq Experiments in Eukaryotes

Published on: November 7, 2025

252

Related Experiment Videos

Last Updated: Dec 29, 2025

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan
11:58

The Replica Set Method: A High-throughput Approach to Quantitatively Measure Caenorhabditis elegans Lifespan

Published on: June 29, 2018

9.9K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.5K
Rup (RNA-seq Usability Assessment Pipeline) - Quality Control for Bulk RNA-seq Experiments in Eukaryotes
05:07

Rup (RNA-seq Usability Assessment Pipeline) - Quality Control for Bulk RNA-seq Experiments in Eukaryotes

Published on: November 7, 2025

252

Area of Science:

  • Pharmacokinetics and Drug Development
  • Biostatistics and Regulatory Science

Background:

  • Software validation is crucial for bioequivalence trials, especially with average bioequivalence and expanding limits.
  • Standardized datasets are needed to ensure software reliability and regulatory compliance.

Purpose of the Study:

  • To define reference datasets with known results for qualifying and validating bioequivalence trial software.
  • To release 30 public domain datasets and propose consensus results for validation targets.

Main Methods:

  • Evaluated 30 reference datasets using seven different software packages.
  • Applied methods proposed by the European Medicines Agency for bioequivalence trial analysis.

Main Results:

  • All software packages achieved agreement for the estimation of the coefficient of variation within-subject (CVwR) and Method A.
  • Slight discrepancies were noted in two packages for Method B on highly incomplete datasets due to differing degrees of freedom approximations.

Conclusions:

  • All evaluated software packages are suitable for estimating CVwR and Method A.
  • Method B may show minor variations in rare borderline cases due to approximations in degrees of freedom, potentially impacting decisions.